MaxCyte Quarterly Income Statement
NASDAQ: MXCTHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MaxCyte revenue and earnings
In the quarter ended Sep 30, 2026, MaxCyte generated $10.2 million in revenue, up 48.7% from the same quarter a year earlier. MaxCyte reported a net loss of $4.8 million, compared with a loss of $12.4 million a year earlier. Gross margin was 83.4% (up from 76.6%) and operating margin -59.5%.
Diluted earnings per share came in at -$0.05.
Summary generated from market data by MetaCap's automated system. Methodology
MaxCyte income statement (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.15M | 7.27M | 9.65M | 7.30M | 6.83M | 8.51M | 10.39M | 8.69M | 8.16M | 10.43M | 11.34M | 15.66M |
| Revenue growth (YoY) | +48.66% | -14.53% | -7.11% | -16.02% | -16.35% | -18.43% | -8.39% | -44.51% | +2.00% | +15.33% | +32.25% | +26.10% |
| Cost of Revenue | 1.68M | 1.68M | 1.57M | 1.61M | 1.60M | 1.52M | 1.50M | 2.28M | 1.93M | 1.49M | 1.40M | 1.57M |
| Gross Profit | 8.47M | 5.60M | 8.08M | 5.69M | 5.23M | 6.99M | 8.89M | 6.41M | 6.24M | 8.94M | 9.94M | 14.09M |
| Operating Expenses | 14.51M | 15.83M | 14.27M | 16.92M | 19.38M | 21.21M | 21.19M | 19.31M | 20.29M | 20.91M | 22.21M | 22.19M |
| Research & Development | 2.87M | 4.25M | 3.86M | 3.33M | 5.32M | 6.27M | 5.90M | 4.61M | 5.32M | 5.62M | 6.68M | 5.84M |
| Selling, General & Admin | 10.77M | 10.62M | 9.39M | 8.99M | 9.96M | 13.87M | 14.22M | 13.68M | 13.95M | 14.26M | 14.47M | 15.28M |
| Operating Income | -6.04M | -10.23M | -6.18M | -11.23M | -14.15M | -14.23M | -12.29M | -12.90M | -14.05M | -11.97M | -12.28M | -8.10M |
| Other Income (Expense) | 1.28M | 1.36M | 1.44M | 1.63M | 1.73M | 1.87M | 2.03M | 2.30M | 2.50M | 2.59M | 2.75M | 2.82M |
| Pretax Income | -4.76M | -8.87M | -4.75M | -9.60M | -12.42M | -12.36M | -10.26M | -10.60M | -11.56M | -9.38M | -9.53M | -5.28M |
| Net Income | -4.76M | -8.87M | -4.75M | -9.60M | -12.42M | -12.36M | -10.26M | -10.60M | -11.56M | -9.38M | -9.53M | -5.28M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.05 | -0.08 | -0.04 | -0.08 | -0.12 | -0.12 | -0.10 | -0.10 | -0.11 | -0.09 | -0.09 | -0.05 |
| EPS (Diluted) | -0.05 | -0.08 | -0.04 | -0.08 | -0.12 | -0.12 | -0.10 | — | -0.11 | -0.09 | — | -0.05 |
| Shares Outstanding (Basic) | 103.54M | 106.82M | 106.88M | — | 106.61M | 106.40M | 105.95M | — | 105.11M | 104.64M | 104.09M | — |
| Shares Outstanding (Diluted) | 103.54M | 106.82M | 106.88M | — | 106.61M | 106.40M | 105.95M | — | 105.11M | 104.64M | 104.09M | — |
| EBITDA | -5.14M | -9.25M | -5.14M | -10.15M | -13.08M | -13.13M | -11.20M | -11.84M | -12.99M | -10.89M | -11.16M | -6.99M |
| Gross Margin | 83.41% | 76.96% | 83.74% | 77.95% | 76.63% | 82.14% | 85.59% | 73.76% | 76.38% | 85.73% | 87.63% | 89.96% |
| Operating Margin | -59.51% | -140.72% | -64.09% | -153.78% | -207.19% | -167.24% | -118.33% | -148.41% | -172.13% | -114.76% | -108.23% | -51.68% |
| Net Margin | -46.91% | -122.05% | -49.22% | -131.45% | -181.81% | -145.26% | -98.76% | -121.90% | -141.56% | -89.89% | -83.99% | -33.69% |
This table shows 12 quarterly periods of MaxCyte's income statement, from Q3 2026 back to Q4 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MXCT's reporting calendar. What is a income statement?